Structure-activity analysis of biased agonism at the human adenosine A3 receptor

Molecular Pharmacology

Volumn 90, Issue 1, 2016, Pages 12-22

  Baltos, Jo Anne ^a   Paoletta, Silvia ^b   Nguyen, Anh T N ^a   Gregory, Karen J ^a   Tosh, Dilip K ^b   Christopoulos, Arthur ^a   Jacobson, Kenneth A ^b   May, Lauren T ^a  

^a MONASH UNIVERSITY   (Australia)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE A3 RECEPTOR; PICLIDENOSON; ADENOSINE; ADENOSINE A3 RECEPTOR AGONIST; LIGAND; N(6)-(3-IODOBENZYL)-5'-N-METHYLCARBOXAMIDOADENOSINE;

ANIMAL CELL; ARTICLE; CALCIUM MOBILIZATION ASSAY; CELL SURVIVAL; CHO CELL LINE; CONFORMATION; DRUG RECEPTOR BINDING; INTRACELLULAR SIGNALING; MOLECULAR DOCKING; MOLECULAR MODEL; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STABLE EXPRESSION; STRUCTURE ACTIVITY RELATION; ANALOGS AND DERIVATIVES; ANIMAL; CHEMISTRY; CRICETULUS; DRUG EFFECTS; HAMSTER; HUMAN; METABOLISM;

ADENOSINE; ADENOSINE A3 RECEPTOR AGONISTS; ANIMALS; CHO CELLS; CRICETINAE; CRICETULUS; HUMANS; LIGANDS; MOLECULAR DOCKING SIMULATION; RECEPTOR, ADENOSINE A3; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84976440477     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.116.103283     Document Type: Article

References (53)

1. Baltos J-A, Gregory KJ, White PJ, Sexton PM, Christopoulos A, and May LT (2016) Quantification of adenosine A1 receptor biased agonism: implications for drug discovery. Biochem Pharmacol 99:101-112.
2. Bar-Yehuda S, Stemmer SM, Madi L, Castel D, Ochaion A, Cohen S, Barer F, Zabutti A, Perez-Liz G, and Del Valle L et al. (2008) The A3 adenosine receptor agonist CF102 induces apoptosis of hepatocellular carcinoma via de-regulation of the Wnt and NF-kappaB signal transduction pathways. Int J Oncol 33:287-295.
3. Barbhaiya H, McClain R, Ijzerman A, and Rivkees SA (1996) Site-directed mutagenesis of the human A1 adenosine receptor: influences of acidic and hydroxy residues in the first four transmembrane domains on ligand binding. Mol Pharmacol 50:1635-1642.
4. Boerrigter G, Lark MW, Whalen EJ, Soergel DG, Violin JD, and Burnett JC, Jr (2011) Cardiorenal actions of TRV120027, a novel ß-arrestin-biased ligand at the angiotensin II type I receptor, in healthy and heart failure canines: a novel therapeutic strategy for acute heart failure. Circ Heart Fail 4:770-778.
5. Chen X, Sassano MF, Zheng L, Setola V, Chen M, Bai X, Frye SV, Wetsel WC, Roth BL, and Jin J (2012) Structure-functional selectivity relationship studies of b-arrestin-biased dopamine D2 receptor agonists. J Med Chem 55:7141-7153.
6. Doré AS, Robertson N, Errey JC, Ng I, Hollenstein K, Tehan B, Hurrell E, Bennett K, Congreve M, and Magnani F et al. (2011) Structure of the adenosine A2A receptor in complex with ZM241385 and the xanthines XAC and caffeine. Structure 19: 1283-1293.
7. Fishman P, Bar-Yehuda S, Liang BT, and Jacobson KA (2012) Pharmacological and therapeutic effects of A3 adenosine receptor agonists. Drug Discov Today 17: 359-366.
8. Fishman P, Bar-Yehuda S, Madi L, and Cohn I (2002) A3 adenosine receptor as a target for cancer therapy. Anticancer Drugs 13:437-443.
9. Fishman P, Cohen S, and Bar-Yehuda S (2013) Targeting the A3 adenosine receptor for glaucoma treatment (review). Mol Med Rep 7:1723-1725.
10. Fossetta J, Jackson J, Deno G, Fan X, Du XK, Bober L, Soudé-Bermejo A, de Bouteiller O, Caux C, and Lunn C et al. (2003) Pharmacological analysis of calcium responses mediated by the human A3 adenosine receptor in monocyte-derived dendritic cells and recombinant cells. Mol Pharmacol 63:342-350.
11. Fredholm BB, Ijzerman AP, Jacobson KA, Klotz KN, and Linden J (2001) International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 53:527-552.
12. Fredholm BB, Ijzerman AP, Jacobson KA, Linden J, and Müller CE (2011) International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors-an update. Pharmacol Rev 63:1-34.
13. Gao Z-G and Jacobson KA (2008) Translocation of arrestin induced by human A3 adenosine receptor ligands in an engineered cell line: comparison with G proteindependent pathways. Pharmacol Res 57:303-311.
14. Gao Z-G, Kim S-K, Gross AS, Chen A, Blaustein JB, and Jacobson KA (2003) Identification of essential residues involved in the allosteric modulation of the human A3 adenosine receptor. Mol Pharmacol 63:1021-1031.
15. Gao Z-G, Verzijl D, Zweemer A, Ye K, Göblyös A, Ijzerman AP, and Jacobson KA (2011) Functionally biased modulation of A(3) adenosine receptor agonist efficacy and potency by imidazoquinolinamine allosteric enhancers. Biochem Pharmacol 82:658-668.
16. Guo D, Mulder-Krieger T, Ijzerman AP, and Heitman LH (2012) Functional efficacy of adenosine A2A receptor agonists is positively correlated to their receptor residence time. Br J Pharmacol 166:1846-1859.
17. Headrick JP, and Lasley RD (2009) Adenosine receptors and reperfusion injury of the heart. Handb Exp Pharmacol 193:189-214.
18. Holloway AC, Qian H, Pipolo L, Ziogas J, Miura S, Karnik S, Southwell BR, Lew MJ, and Thomas WG (2002) Side-chain substitutions within angiotensin II reveal different requirements for signaling, internalization, and phosphorylation of type 1A angiotensin receptors. Mol Pharmacol 61:768-777.
19. Jaakola V-P, Griffith MT, Hanson MA, Cherezov V, Chien EYT, Lane JR, Ijzerman AP, and Stevens RC (2008) The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist. Science 322:1211-1217.
20. Jacobson KA (1998) Adenosine A3 receptors: novel ligands and paradoxical effects. Trends Pharmacol Sci 19:184-191.
21. Jacobson KA and Gao Z-G (2006) Adenosine receptors as therapeutic targets. Nat Rev Drug Discov 5:247-264.
22. Jacobson KA, Ji X, Li A-H, Melman N, Siddiqui MA, Shin K-J, Marquez VE, and Ravi RG (2000) Methanocarba analogues of purine nucleosides as potent and selective adenosine receptor agonists. J Med Chem 43:2196-2203.
23. Jacobson KA, Klutz AM, Tosh DK, Ivanov AA, Preti D, and Baraldi PG (2009) Medicinal chemistry of the A3 adenosine receptor: agonists, antagonists, and receptor engineering. Handb Exp Pharmacol 193:123-159.
24. Kenakin T (2011) Functional selectivity and biased receptor signaling. J Pharmacol Exp Ther 336:296-302.
25. Kenakin T, Watson C, Muniz-Medina V, Christopoulos A, and Novick S (2012) A simple method for quantifying functional selectivity and agonist bias. ACS Chem Neurosci 3:193-203.
26. Kepp O, Galluzzi L, Lipinski M, Yuan J, and Kroemer G (2011) Cell death assays for drug discovery. Nat Rev Drug Discov 10:221-237.
27. Kim HO, Ji XD, Siddiqi SM, Olah ME, Stiles GL, and Jacobson KA (1994) 2-Substitution of N6-benzyladenosine-59-uronamides enhances selectivity for A3 adenosine receptors. J Med Chem 37:3614-3621.
28. Klein Herenbrink C, Sykes DA, Donthamsetti P, Canals M, Coudrat T, Shonberg J, Scammells PJ, Capuano B, Sexton PM, and Charlton SJ et al. (2016) The role of kinetic context in apparent biased agonism at GPCRs. Nat Commun 7:10842.
29. Langemeijer EV, Verzijl D, Dekker SJ, and Ijzerman AP (2013) Functional selectivity of adenosine A1 receptor ligands? Purinergic Signal 9:91-100.
30. Liu W, Chun E, Thompson AA, Chubukov P, Xu F, Katritch V, Han GW, Roth CB, Heitman LH, and Ijzerman AP et al. (2012) Structural basis for allosteric regulation of GPCRs by sodium ions. Science 337:232-236.
31. Manning BD and Cantley LC (2007) AKT/PKB signaling: navigating downstream. Cell 129:1261-1274.
32. Matot I, Weiniger CF, Zeira E, Galun E, Joshi BV, and Jacobson KA (2006) A3 adenosine receptors and mitogen-activated protein kinases in lung injury following in vivo reperfusion. Crit Care 10:R65.
33. May LT, Avlani VA, Langmead CJ, Herdon HJ, Wood MD, Sexton PM, and Christopoulos A (2007) Structure-function studies of allosteric agonism at M2 muscarinic acetylcholine receptors. Mol Pharmacol 72:463-476.
34. Merighi S, Benini A, Mirandola P, Gessi S, Varani K, Leung E, Maclennan S, Baraldi PG, and Borea PA (2006) Modulation of the Akt/Ras/Raf/MEK/ERK pathway by A3 adenosine receptor. Purinergic Signal 2:627-632.
35. Müller CE and Jacobson KA (2011) Recent developments in adenosine receptor ligands and their potential as novel drugs. BBA 1808:1290-1308.
36. Nygaard R, Valentin-Hansen L, Mokrosinski J, Frimurer TM, and Schwartz TW (2010) Conserved water-mediated hydrogen bond network between TM-I, -II, -VI, and -VII in 7TM receptor activation. J Biol Chem 285:19625-19636.
37. Rosenkilde MM, Benned-Jensen T, Frimurer TM, and Schwartz TW (2010) The minor binding pocket: a major player in 7TM receptor activation. Trends Pharmacol Sci 31:567-574.
38. Schulte G and Fredholm BB (2002) Signaling pathway from the human adenosine A3 receptor expressed in Chinese hamster ovary cells to the extracellular signalregulated kinase 1/2. Mol Pharmacol 62:1137-1146.
39. Shonberg J, Herenbrink CK, López L, Christopoulos A, Scammells PJ, Capuano B, and Lane JR (2013) A structure-activity analysis of biased agonism at the dopamine D2 receptor. J Med Chem 56:9199-9221.
40. Stewart GD, Valant C, Dowell SJ, Mijaljica D, Devenish RJ, Scammells PJ, Sexton PM, and Christopoulos A (2009) Determination of adenosine A1 receptor agonist and antagonist pharmacology using Saccharomyces cerevisiae: implications for ligand screening and functional selectivity. J Pharmacol Exp Ther 331:277-286.
41. Sykes DA, Dowling MR, and Charlton SJ (2009) Exploring the mechanism of agonist efficacy: a relationship between efficacy and agonist dissociation rate at the muscarinic M3 receptor. Mol Pharmacol 76:543-551.
42. Tosh DK, Deflorian F, Phan K, Gao Z-G, Wan TC, Gizewski E, Auchampach JA, and Jacobson KA (2012a) Structure-guided design of A3 adenosine receptorselective nucleosides: combination of 2-arylethynyl and bicyclo[3.1.0]hexane substitutions. J Med Chem 55:4847-4860.
43. Tosh DK, Paoletta S, Phan K, Gao Z-G, and Jacobson KA (2012b) Truncated nucleosides as A3 adenosine receptor ligands: Combined 2-arylethynyl and bicyclohexane substitutions. ACS Med Chem Lett 3:596-601.
44. Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka B, Weinstein H, Javitch JA, Roth BL, Christopoulos A, and Sexton PM et al. (2007) Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther 320: 1-13.
45. Vaidehi N and Kenakin T (2010) The role of conformational ensembles of seven transmembrane receptors in functional selectivity. Curr Opin Pharmacol 10: 775-781.
46. Valant C, May LT, Aurelio L, Chuo CH, White PJ, Baltos JA, Sexton PM, Scammells PJ, and Christopoulos A (2014) Separation of on-target efficacy from adverse effects through rational design of a bitopic adenosine receptor agonist. Proc Natl Acad Sci USA 111:4614-4619.
47. van der Westhuizen ET, Breton B, Christopoulos A, and Bouvier M (2014) Quantification of ligand bias for clinically relevant β2-adrenergic receptor ligands: implications for drug taxonomy. Mol Pharmacol 85:492-509.
48. Verzijl D and Ijzerman AP (2011) Functional selectivity of adenosine receptor ligands. Purinergic Signal 7:171-192.
49. Violin JD, DeWire SM, Yamashita D, Rominger DH, Nguyen L, Schiller K, Whalen EJ, Gowen M, and Lark MW (2010) Selectively engaging b-arrestins at the angiotensin II type 1 receptor reduces blood pressure and increases cardiac performance. J Pharmacol Exp Ther 335:572-579.
50. Volpini R, Buccioni M, Dal Ben D, Lambertucci C, Lammi C, Marucci G, Ramadori AT, Klotz K-N, and Cristalli G (2009) Synthesis and biological evaluation of 2-alkynyl-N6-methyl-59-N-methylcarboxamidoadenosine derivatives as potent and highly selective agonists for the human adenosine A3 receptor. J Med Chem 52: 7897-7900.
51. Wada T and Penninger JM (2004) Mitogen-activated protein kinases in apoptosis regulation. Oncogene 23:2838-2849.
52. Wootten D, Savage EE, Willard FS, Bueno AB, Sloop KW, Christopoulos A, and Sexton PM (2013) Differential activation and modulation of the glucagon-like peptide-1 receptor by small molecule ligands. Mol Pharmacol 83:822-834.
53. Xu F, Wu H, Katritch V, Han GW, Jacobson KA, Gao ZG, Cherezov V, and Stevens RC (2011) Structure of an agonist-bound human A2A adenosine receptor. Science 332:322-327.